Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving Average - Here's Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.33 and traded as low as $5.52. Karyopharm Therapeutics shares last traded at $6.07, with a volume of 133,530 shares traded.

Analysts Set New Price Targets

A number of research firms have issued reports on KPTI. Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada restated an "outperform" rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright boosted their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Karyopharm Therapeutics Stock Up 11.2 %

The business's fifty day moving average is $5.71 and its 200-day moving average is $9.25. The stock has a market capitalization of $64.40 million, a PE ratio of -7.37 and a beta of 0.32.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping analysts' consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. As a group, sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KPTI. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the fourth quarter worth approximately $27,000. Focus Partners Wealth acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. purchased a new position in Karyopharm Therapeutics in the fourth quarter valued at about $32,000. Two Sigma Advisers LP boosted its position in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock worth $52,000 after buying an additional 45,400 shares during the period. Finally, Opti Capital Management LP purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $85,000. Institutional investors and hedge funds own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).